We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Siemens Healthineers Commissioned to Provide Lab Services for Turkish Hospitals

By LabMedica International staff writers
Posted on 09 Feb 2017
Print article
Image: Siemens Healthineers has entered into a five-year contract to take over the clinical laboratory service operations for two new hospitals in Turkey (Photo courtesy of QLS).
Image: Siemens Healthineers has entered into a five-year contract to take over the clinical laboratory service operations for two new hospitals in Turkey (Photo courtesy of QLS).
Siemens Healthineers has entered into a five-year contract to take over the clinical laboratory service operations for two new hospitals in Turkey. The hospitals in Bilkent, Ankara, and in Mersin are being built and operated as Public Private Partnership (PPP) by DiA Construction, a subsidiary of DiA, for the Turkish Ministry of Health.

The new hospitals are expected to improve healthcare as part of a Turkish government program to restructure the country's healthcare system, which began in 2003. According to the Turkish government, the Bilkent health campus, which has nearly 3,800 beds and an affiliated hotel, congress center and commercial area, is the largest project in the healthcare sector to be ever constructed from scratch in the country. From mid-2018, over 10,000 medical staff will manage almost 25,000 patients daily at the Bilkent health campus, while the hospital in Mersin, which became operational towards the end of January 2017, will hold about 1,300 beds.

Siemens Healthineers will operate the laboratories at both the hospitals in partnership with lab doctors from Turkey's Ministry of Health. The company will assume the laboratory services for biochemistry, microbiology, hematology, immunology, emergency, genetics, pathology and point of care testing within these hospitals. It also will provide the design, medical and technical equipment, appliances, consumables, service and maintenance, apart from the laboratory technical staff. The contract is expected to grant minimum revenue of nearly Euro 30 million, based on guaranteed annual test volumes, and is likely to surpass Euro 100 million, based on anticipated test volumes.

"It was important for us to have a partner that not only came with enough experience in the hospital environment, but also was strong on technical innovation," said Hakan Adanalı, Director of Clinical Support Services in DiA. "We expect, that around 92 million patients will benefit from the partnership over the next five years."

"This project combines our expertise in equipping laboratories with our service portfolio. It is a milestone for us and, at the same time, also a proof point for how we enable our customers to meet their current challenges and to excel in their respective environments. The new business model is designed to support our customers in increasing efficiency and containing costs right from the beginning," said Bernd Montag, Chief Executive Officer, Siemens Healthineers. "We have developed a customized solution for our partner DiA and the Turkish Ministry of Health that will comprehensively support their clinical business. This order will strengthen our portfolio and is consistent with our strategy."

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.